Institution
Theodor Bilharz Research Institute
Facility•Giza, Egypt•
About: Theodor Bilharz Research Institute is a facility organization based out in Giza, Egypt. It is known for research contribution in the topics: Biomphalaria alexandrina & Schistosoma mansoni. The organization has 802 authors who have published 997 publications receiving 12458 citations.
Topics: Biomphalaria alexandrina, Schistosoma mansoni, Praziquantel, Cirrhosis, Hepatocellular carcinoma
Papers published on a yearly basis
Papers
More filters
••
Inova Fairfax Hospital1, Inova Health System2, RWTH Aachen University3, Pontifical Catholic University of Chile4, Theodor Bilharz Research Institute5, University of Turin6, The Chinese University of Hong Kong7, Marmara University8, University of Sydney9, Shanghai Jiao Tong University10, Emory University11
TL;DR: The authors in this article examined the state of NAFLD among different regions and understand the global trajectory of this disease, an international group of experts came together during the 2017 American Association for the Study of Liver Diseases Global NASFLD Forum and provided a summary of this forum and an assessment of the current state of NASH worldwide.
978 citations
••
TL;DR: The free radical scavenging activity of different fractions obtained from successive fractionation of the six methanol extracts with organic solvents of different polarities; petroleum ether, CHCl 3, EtOAc and n-BuOH; showed that, the EtO Ac and n -BuOH fractions have the high activity with SC 50− 3 fractions have weak activity at SC 50 ≥ 200 and 100μg/ml, respectively as discussed by the authors.
337 citations
••
TL;DR: The results suggest that Nigella sativa oil may play a role against the alterations caused by S. mansoni infection, an effect which may be induced partly by improving the immunological host system and to some extent with its antioxidant effect.
330 citations
••
TL;DR: Treatment with praziquantel (PZQ) has become virtually the sole basis of schistosomiasis control in sub-Saharan Africa and elsewhere, and the drug is reviewed here in the context of the increasing rate that it is being used for this purpose.
Abstract: Treatment with praziquantel (PZQ) has become virtually the sole basis of schistosomiasis control in sub-Saharan Africa and elsewhere, and the drug is reviewed here in the context of the increasing rate that it is being used for this purpose. Attention is drawn to our relative lack of knowledge about the mechanisms of action of PZQ at the molecular level, the need for more work to be done on schistosome isolates that have been collected recently from endemic areas rather than those maintained in laboratory conditions for long periods, and our reliance for experimental work mainly on Schistosoma mansoni, little work having been done on S. haematobium. There is no evidence that resistance to PZQ has been induced in African schistosomes as a result of its large-scale use on that continent to date, but there is also no assurance that PZQ and/or schistosomes are in any way unique and that resistant organisms will not be selected as a result of widespread drug usage. The failure of PZQ to produce complete cures in populations given a routine treatment should therefore solicit considerable concern. With few alternatives to PZQ currently available and/or on the horizon, methods to monitor drug-susceptibility in African schistosomes need to be devised and used to help ensure that this drug remains effective for as long a time as possible.
184 citations
••
TL;DR: The SNP rs12979860 is strongly associated with SVR in patients infected with HCV-4, but not with liver disease severity; analysis of IL28B genotype might be used to guide treatment for these patients.
181 citations
Authors
Showing all 811 results
Name | H-index | Papers | Citations |
---|---|---|---|
Sanaa S. Botros | 23 | 67 | 1953 |
Mohamed Saber | 23 | 178 | 2119 |
Mohamed T. Khayyal | 22 | 97 | 1807 |
Olfat Hammam | 22 | 120 | 1577 |
Yousif F | 17 | 43 | 797 |
Sayed H. Seif el-Din | 16 | 32 | 605 |
Mostafa Ibrahim | 16 | 39 | 701 |
Naglaa M. El-Lakkany | 16 | 39 | 625 |
Samira Saleh | 16 | 47 | 1160 |
Mohamed El Kassas | 15 | 88 | 839 |
Eman El-Ahwany | 15 | 44 | 513 |
Magdy M. Youssef | 15 | 57 | 540 |
Fatma A. Ebeid | 14 | 29 | 530 |
Amina S. Attia | 14 | 32 | 723 |
El-Sayed S. Abdel-Hameed | 13 | 41 | 891 |